Cyclosporine is a drug obtained from a type of soil fungus found in Norway called Tolypocladium inflatum. The drug is valuable in organ transplants because it suppresses the action of certain cells in the body's immune (disease-fighting) system that can reject the transplanted organ. While preventing attacks of these cells, called T cells (or T-helper cells), cyclosporine lets the bulk of the body's immune system function normally and fight general infection.

Cyclosporine is a relatively new drug. It was approved by the U.S. Food and Drug Administration in 1983 for use in all transplant patients. Before the use of cyclosporine, live organs could be transplanted from one body to another, but the drugs necessary to prevent rejection of the foreign tissue weakened the patient's entire immune system. Frequently patients could not survive the severe infections that followed transplants, and mortality (death) rates for transplant patients were discouragingly high. The discovery of cyclosporine brought about a major shift in the success of transplantation.

Cyclosporine lets the bulk of the body's immune system function normally and fight general infection.
Cyclosporine lets the bulk of the body's immune system function normally and fight general infection.

Borel's Studies

Jean-Francois Borel (1934-), a microbiologist working for Sandoz Laboratories in Switzerland, discovered cyclosporine in 1969 when he was vacationing in Norway. Sandoz employees were encouraged to gather samples of naturally occurring organisms for analysis in the laboratory. When Borel visited Hardanger Vidda, a desolate highland plateau in southern Norway, he collected some soil samples and brought them back to Sandoz for testing.

Sandoz Laboratories was involved primarily in antibiotics research, and the purpose of their first series of tests on cyclosporine was to determine the substance's potential as an antibiotic. The tests yielded little of interest as far as antibiotics were concerned, but did show that cyclosporine had distinct immunosuppressive capabilities. Since his doctoral studies involved immunogenetics (the study of how the immune system works), Borel decided that he wanted to learn more about cyclosporine.

Borel ran a second series of tests and found that cyclosporine inhibits the activity of lymphocytes (white blood cells), the part of the immune system that starts the process of detecting and attacking foreign invaders. Lymphocytes aid in the formation of cytotoxic (toxic to cells) T cells. These cells, along with blood cells called monocytes and macrophages, are thought to be responsible for the rejection of transplanted organs. Cyclosporine does not actually destroy the T cells, but fends them off. It acts at an early stage in the life cycle of the T cell, inhibiting its action by blocking the intercellular message carried by a cellular compound called interleukin-2.

A Disappointing Setback

It looked as if Borel had discovered a superior drug for transplantation, but his employer was not sufficiently impressed by the findings he reported in 1972. The estimated costs for production and testing of the drug were too high, and organ transplantation was just getting started. The potential demand for cyclosporine was questionable. Sandoz was unwilling to put the necessary money and energy behind the drug for further exploration.

Two immunologists recognized the importance of Borel's discovery, however, when the researcher presented his results to the British Society of Immunologists in 1976. David White and Sir Roy Calne asked Borel for samples of cyclosporine and began their own clinical studies using organ transplantation in rats. The results were remarkable: rejection was almost nonexistent, and the survival rate was far better than for other immunosuppressants. In mid-1977, White and Calne informed Borel of their findings and requested more samples of cyclosporine to continue their clinical trials, this time on dogs. Borel, hoping to revive Sandoz's interest in cyclosporine, asked White and Calne to present their findings to Sandoz. The pharmaceutical company agreed that the drug looked much more promising now that there was evidence of its effectiveness.

The success of cyclosporine suffered a setback in 1979 when further studies showed it to be nephrotoxic (poisonous to the kidneys) and to cause lymphomas (tumors). These side effects proved to be the result of high doses of the drug. The practice at the time was to administer as much cyclosporine as the body could handle, short of a toxic level. Research later showed it should be given in small amounts, just enough cyclosporine to prevent rejection of a transplanted organ. With the decreased dosage, the lymphoma was eliminated and nephrotoxicity was reduced.

Later research by Thomas Starzl in Colorado indicated that cyclosporine worked most effectively when administered with steroids. In 1983 the Food and Drug Administration approved cyclosporine for use in all transplant patients, but said it must be given only in conjunction with steroids. Cyclosporine must be taken indefinitely by persons who have received organ transplants, however, and the possibility of irreversible kidney failure remains a serious concern.

Cyclosporine is not a perfect drug, but it is the most potent (strong) and specific immunosuppressant available for organ transplant patients. It is effective in treating infections after the surgery, and it is associated with a lower mortality rate among transplant patients. It is commonly used in kidney, heart and lung, liver and pancreas, and bone marrow transplants. Cyclosporine is also used to treat viral and fungal infections and immune disorders, to promote healing of wounds, and in certain kinds of tissue grafts. The drug is also used in treating certain autoimmune diseases such as myasthenia gravis and is being tested for use in treating inflammatory bowel disease.

User Contributions:

Report this comment as inappropriate
Aug 11, 2008 @ 5:17 pm
what is the best antibiotic to use with cyclosporine?
Nabaraj Aryal
Report this comment as inappropriate
Oct 12, 2017 @ 6:06 am
This article is very much informative & useful for transplanted patients.

Comment about this article, ask questions, or add new information about this topic:


Cyclosporine forum